Top Stories
A survey found that 97.3% of patients with cancer said they would trust their oncologist most for serious questions about their cancer’s future, while none selected ChatGPT or AI.
Despite failing to meet the study's primary endpoint, the Galleri test showed a reduction in Stage IV cancers and an increase in early-stage diagnoses.
The expanded label makes xT CDx the first US-approved test for both tumour-only and tumour-normal genomic profiling.
The smart ring maker added blood pressure signals, health records, GLP-1 tracking and access to licensed providers inside the Oura App.
The company reported that patients identified as Onclara IO High had a median overall survival of 484 days, compared with 155 days for those with 'low' designation.
Conference News
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, launched the novus V55 system - a next-generation triple quadrupole mass spe...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, introduced platform-wide advancements across its accurate mass ZenoTOF line....
Paradigm Health's Scalable Platform for Integrated Research and Evidence (SPIRE) helps trial sponsors generate high-quality clinical trial data across community healthcare practicesColumbus, Ohio and ...
LONDON, UNITED KINGDOM, June 1, 2026 /EINPresswire.com/ -- Sciensus, a leading European life sciences organisation focused on accelerating patients' access to life-saving medicines, and Rare Patient V...
Company to highlight enterprise imaging workflows, enterprise viewing, and digital pathology capabilities at Booth 608BURLINGTON, Vt., June 1, 2026 /PRNewswire/ -- Mach7 Technologies (ASX:M7T), a prov...
